Suppression of Established Puerperal Lactation with 2-Br-alpha-Ergocryptine Methane Sulphonate (CB 154)

Abstract

Seppälä, M., Ylinen, O., Sternthal, V., Soiva, K. and Vara, P. (Dept. II of Obstetrics and Gynaecology, University Central Hospital, Helsinki, Midwifery Institute, Helsinki, Finland and Medical‐Biological Research Department, Sandoz, Ltd., Basle, Switzerland).

Prevention and Suppression of Post‐partum Lactation With 2‐bromo‐alpha‐ergocryptine (Cb‐154)

“…The most widely used method of suppression or inhibiting post-partum lactation at the present time is a Combination or a single application of the following: (a) administration of oestrogens alone or together with androgens; (b) breast compression; (c) restriction of fluid intake. However, because of the possible increase of thromboembolic disease (Daniel et al, 1967;Jeffcoate et al, 1968), associated with hormonal inhibition and the frequent rebound engorgement (as high as 50%) and withdrawal bleeding (30%) encountered (Winter Falzone et af., 1974;Rolland & Schellekens, 1973;Seppala et al, 1975;Utian et al, 1975;Varga et al, 1972;Walker et aI., 1975). At the initiation of this study, three previous studies (Brun del Re et a/., 1973;Rolland & Schellekens, 1973;Varga et ~l .…”

Inhibition of Puerperal Lactation. A Double Blind Study of Bromocriptine and Placebo

“…Lactogenesis is dependent on the raised level of pituitary prolactin secretion. Recent papers (1)(2)(3)(4)(5)(6)(7)(8)(9)(10) have suggested that this can be lowered by the Dopamine agonist Bromocriptine, thus effectively suppressing lactation.…”